Repligen (RGEN)
(Delayed Data from NSDQ)
$171.28 USD
+13.64 (8.65%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $171.37 +0.09 (0.05%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RGEN 171.28 +13.64(8.65%)
Will RGEN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RGEN
PBYI vs. RGEN: Which Stock Is the Better Value Option?
Repligen (RGEN) Stock Down on Q4 Earnings Miss, Revenues Fall Y/Y
RGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Repligen (RGEN) Lags Q4 Earnings and Revenue Estimates
Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?
Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?
Other News for RGEN
HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday
Baron Health Care Fund Q1 2024 Shareholder Letter
Danaher gains as Q1 results exceed expectations
Positive Report for Repligen (RGEN) from Craig-Hallum
Repligen to Report First Quarter 2024 Financial Results